Whilst erlotinib is widely recognised as the first‐line therapy for advanced NSCLC patients with positive EGFR mutations, it has also shown clinical benefits in other settings, such as maintenance therapy and as a second or third‐line treatment.48, 49, 50. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.